Matches in Wikidata for { <http://www.wikidata.org/entity/Q63383246> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q63383246 description "article scientifique publié en 2012" @default.
- Q63383246 description "im Jahr 2012 veröffentlichter wissenschaftlicher Artikel" @default.
- Q63383246 description "wetenschappelijk artikel" @default.
- Q63383246 description "наукова стаття, опублікована в січні 2012" @default.
- Q63383246 name "2.244 PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF OPICAPONE, A NOVEL COMT INHIBITOR, DURING FIRST ADMINISTRATION TO HEALTHY MALE SUBJECTS" @default.
- Q63383246 name "2.244 PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF OPICAPONE, A NOVEL COMT INHIBITOR, DURING FIRST ADMINISTRATION TO HEALTHY MALE SUBJECTS" @default.
- Q63383246 type Item @default.
- Q63383246 label "2.244 PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF OPICAPONE, A NOVEL COMT INHIBITOR, DURING FIRST ADMINISTRATION TO HEALTHY MALE SUBJECTS" @default.
- Q63383246 label "2.244 PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF OPICAPONE, A NOVEL COMT INHIBITOR, DURING FIRST ADMINISTRATION TO HEALTHY MALE SUBJECTS" @default.
- Q63383246 prefLabel "2.244 PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF OPICAPONE, A NOVEL COMT INHIBITOR, DURING FIRST ADMINISTRATION TO HEALTHY MALE SUBJECTS" @default.
- Q63383246 prefLabel "2.244 PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF OPICAPONE, A NOVEL COMT INHIBITOR, DURING FIRST ADMINISTRATION TO HEALTHY MALE SUBJECTS" @default.
- Q63383246 P1433 Q63383246-67E60516-F384-4924-8186-18009D176A3D @default.
- Q63383246 P1476 Q63383246-506B1A6B-9731-4863-A6E7-95A55440ADC8 @default.
- Q63383246 P2093 Q63383246-408A06E5-0966-418D-BF49-A18A65972C69 @default.
- Q63383246 P2093 Q63383246-6AA61F61-5904-4F28-BA6E-1277B9309FF5 @default.
- Q63383246 P2093 Q63383246-7818C01A-0D43-4F61-BB73-6C7B979E2109 @default.
- Q63383246 P2093 Q63383246-88C226DE-857A-46BD-A23B-1D598402BE1D @default.
- Q63383246 P2093 Q63383246-97DA2014-9D83-4644-92F8-7832A15DED05 @default.
- Q63383246 P2093 Q63383246-B3A1C13A-A3B4-4E8E-90D7-AC232EDA0F1A @default.
- Q63383246 P2093 Q63383246-BFD51D83-2AE8-4805-9BD6-9C9BD0D9929A @default.
- Q63383246 P2093 Q63383246-D2F0219C-CBF8-4D9D-B703-E428713088CB @default.
- Q63383246 P304 Q63383246-B2CE290F-463C-458E-8AF6-AD7B5FAE9208 @default.
- Q63383246 P31 Q63383246-8AF26AA6-DD10-408F-A15C-1C7D958B46C7 @default.
- Q63383246 P356 Q63383246-09E7B232-C2BA-4C11-A88D-E5A6095CF21B @default.
- Q63383246 P478 Q63383246-C9C7D308-7A19-4266-A0A9-CD8DD0676E18 @default.
- Q63383246 P577 Q63383246-4582D310-11CA-4CED-AD0D-66B78DA30B95 @default.
- Q63383246 P921 Q63383246-C686E8E8-6462-496D-9B4A-D9AAE4EF58FA @default.
- Q63383246 P921 Q63383246-DCAD9118-818B-4386-B7B3-391899C3F02B @default.
- Q63383246 P356 S1353-8020(11)70568-5 @default.
- Q63383246 P1433 Q15762600 @default.
- Q63383246 P1476 "2.244 PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF OPICAPONE, A NOVEL COMT INHIBITOR, DURING FIRST ADMINISTRATION TO HEALTHY MALE SUBJECTS" @default.
- Q63383246 P2093 "A. Falcao" @default.
- Q63383246 P2093 "J.F. Rocha" @default.
- Q63383246 P2093 "L. Almeida" @default.
- Q63383246 P2093 "L.C. Wright" @default.
- Q63383246 P2093 "P. Soares-da-Silva" @default.
- Q63383246 P2093 "R. Machado" @default.
- Q63383246 P2093 "R. Pinto" @default.
- Q63383246 P2093 "T. Nunes" @default.
- Q63383246 P304 "S126" @default.
- Q63383246 P31 Q13442814 @default.
- Q63383246 P356 "10.1016/S1353-8020(11)70568-5" @default.
- Q63383246 P478 "18" @default.
- Q63383246 P577 "2012-01-01T00:00:00Z" @default.
- Q63383246 P921 Q323936 @default.
- Q63383246 P921 Q725307 @default.